Nurix Therapeutics, Inc.
For the period ended May 19, 2025. Filed Mar 28, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 19, 2025 · Filed Mar 28, 2025
Contents
Compensation Determination Process
Role of the Compensation Committee
The Compensation Committee establishes our compensation philosophy and objectives, determines the structure, components and other elements of executive compensation, and reviews and approves the compensation of the NEOs or recommends it for approval by the Board. The Compensation Committee structures the executive compensation program to accomplish its articulated compensation objectives in light of the compensation philosophy described above. From time to time, and in conjunction with our Compensation Committee, the independent members of our Board may also be involved in setting the compensation of our CEO and other NEOs and determining the corporate objectives upon which our short-term and long-term incentives are based.
The Compensation Committee annually reviews compensation policies, practices and procedures to determine if any updates are needed. The Compensation Committee also approves, or recommends to the Board for approval, the corporate objectives associated with our annual performance-based cash incentive program, as well as assessing the Company’s performance against those corporate objectives after the end of the year or making a recommendation to the Board as to the extent to which the Company has met those corporate objectives. Our Compensation Committee’s decisions and recommendations regarding executive compensation are based on the Compensation Committee’s assessment of the performance of Nurix and each individual executive officer, as well as other factors, such as prevailing industry trends and the competitive market for executive talent.
The Compensation Committee meets periodically throughout the year to manage and evaluate our executive compensation program, and generally determines executive compensation on an annual basis, typically at the beginning of each fiscal year; however, decisions may occur during the year for new hires, promotions or other special circumstances as the Compensation Committee determines appropriate.
Role of the CEO and Management
The Compensation Committee generally seeks the input of our CEO when discussing the performance of, and compensation for, our executive officers, including the NEOs other than the CEO. Our CEO plays an important role in developing both our annual and long-term strategic objectives and goals, which are reviewed and approved by the Compensation Committee and the Board. Further, our CEO also provides valuable perspective in determining our performance against those goals.
Our CEO annually reviews the performance of our other executive officers, including our other NEOs, and presents his conclusions to the Compensation Committee. He then provides corresponding compensation recommendations regarding base salary adjustments, annual performance-based cash compensation targets and payouts, and equity awards. The Compensation Committee considers the CEO’s input as one factor in its deliberations to determine the compensation of our executive officers, including our other NEOs. The Compensation Committee gives significant weight to the recommendations of the CEO in light of his greater familiarity with the day-to-day performance of his direct reports and the importance of incentive compensation in driving the execution of managerial initiatives developed and led by the CEO.
While the CEO may attend Compensation Committee meetings, the CEO may not be present during voting or deliberations on his compensation.
In addition, other members of management may attend Compensation Committee meetings to provide background information or advice, or to answer Compensation Committee member questions, including with respect to the financial, accounting, tax and retention implications of various compensation decisions.
Role of the Independent Compensation Consultant
The Compensation Committee recognizes that there is value in procuring independent, objective expertise in connection with fulfilling its duties and, pursuant to its charter, the Compensation Committee has the authority to select and retain advisors to assist it with carrying out its duties and responsibilities.
The Compensation Committee has engaged the services of an independent compensation consultant, the Human Capital Solutions practice of Aon plc (Aon), to assist it in connection with making executive compensation decisions. The Compensation Committee has the authority, under its charter, to retain, terminate and set the terms of the Company’s relationship with Aon or any other outside advisors that assist the Compensation Committee in carrying out its responsibilities.
The Compensation Committee annually assesses the independence of Aon pursuant to SEC and Nasdaq rules. The Compensation Committee assessed the independence of Aon consistent with Nasdaq listing standards and concluded that the engagement of Aon does not raise any conflict of interest.
For our fiscal year 2024, Aon assisted the Compensation Committee with, among other things:
| • | Providing compensation-related data for a peer group of companies to serve as a basis for assessing competitive compensation practices; |
|---|
| • | Reviewing and assessing our current non-employee director, CEO and other executive officer compensation policies and practices and equity profile, relative to market practices; |
|---|
| • | Reviewing and assessing our current executive compensation program relative to market practices to identify any potential changes or enhancements to be brought to the attention of the Compensation Committee; and |
|---|
| • | Reviewing market practices regarding base salary, bonus and equity programs. |
|---|
While the Compensation Committee took into consideration the review and recommendations of Aon when making decisions about our executive compensation program, ultimately, the Compensation Committee made its own independent decisions in determining our executives’ compensation.
Consideration of Comparative Market Data
The Compensation Committee believes that obtaining relevant market and benchmark data is important to making determinations about executive compensation. This information provides a solid reference point for making decisions and very helpful context, even though, relative to other companies, there are differences and unique aspects of the Company.
With Aon’s assistance and input, the Compensation Committee annually adopts a peer group of companies that it uses as a reference group to provide a broad perspective on competitive pay levels and practices.
The Compensation Committee reviews and approves the peer group companies that are used to evaluate competitive market compensation. In doing so, the Compensation Committee seeks to approve a peer group that is representative of the sector in which we operate and includes companies within an appropriate defined range in terms of key attributes.
In July 2023, the Compensation Committee determined that our peer group for determining the compensation of our NEOs in 2024 would consist of pre-commercial biopharmaceutical/biotechnology companies. In general, the selection criteria consisted of the following:
| • | market capitalizations between $175 million and $1.5 billion, |
|---|
| • | headcount generally between 75 and 600 employees, and |
|---|
| • | preference given to companies that went public within the last five years and those located in the San Francisco Bay area or in other biotech hubs. |
|---|
Based on these criteria, the peer group for setting 2024 compensation consisted of the following 23 companies*:
| 1. Arcus Biosciences, Inc. | 9. iTeos Therapeutics, Inc. | 17. RAPT Therapeutics, Inc. |
|---|---|---|
| 2. Arvinas, Inc. | 10. Kezar Life Sciences, Inc. | 18. Relay Therapeutics, Inc. |
| 3. C4 Therapeutics, Inc. | 11. Kura Oncology, Inc. | 19. Replimune Group, Inc. |
| 4. Erasca, Inc. | 12. Kymera Therapeutics, Inc. | 20. Revolution Medicines, Inc. |
| 5. Foghorn Therapeutics, Inc. | 13. Mersana Therapeutics, Inc. | 21. Sutro Biopharma, Inc. |
| 6. Gritstone bio, Inc. | 14. Monte Rosa Therapeutics, Inc. | 22. Tango Therapeutics, Inc. |
| 7. IDEAYA Biosciences, Inc. | 15. ORIC Pharmaceuticals, Inc. | 23. Zentalis Pharmaceuticals, Inc. |
| 8. IGM Biosciences, Inc. | 16. Prelude Therapeutics, Inc. |
| * | Reflects the removal of the following companies from our 2023 peer group: Allogene Therapeutics, Inc.; Gossamar Bio, Inc.; Kronos Bio, Inc.; Nkarta, Inc.; and Turning Point Therapeutics, Inc. Also reflects the addition of the following companies to our 2024 peer group: Erasca, Inc.; Foghorn Therapeutics, Inc.; Gritstone bio, Inc.; Kura Oncology, Inc., Mersana Therapeutics, Inc., Monte Rosa Therapeutics, Inc., Prelude Therapeutics, Inc., and Tango Therapeutics, Inc. |
|---|
The Compensation Committee utilizes the compensation of executive officers of the companies in this peer group as one reference point in its compensation decisions, along with various other factors, such as the individual’s performance and experience and competitive market conditions.
Additionally, when considering the establishment of 2024 compensation levels for our NEOs, the Compensation Committee, upon recommendation from Aon, supplemented the 2024 peer group market data with data derived from the Radford 2023 Global Life Science Survey for public pre-commercial biopharmaceutical companies. This survey data was used to obtain a general understanding of the compensation practices of companies similar to ours at the time.
The Compensation Committee believes that the compensation practices of our peer group and the applicable survey data provided us with appropriate compensation reference points for evaluating and determining the compensation of our NEOs during 2024.
Say-on-Pay Results
At the 2024 Annual Meeting, our stockholders approved the compensation of our NEOs on an advisory basis (commonly known as a “say-on-pay” proposal), with approximately 88.3% of the votes cast “For” such approval. Our Compensation Committee interpreted stockholder approval of our executive compensation program at such a level as indicating that a substantial majority of stockholders view our executive compensation program as correctly aligned with the current stage of our company’s maturity and appropriately designed to attract and retain top-tier executives in a highly competitive market. Consequently, our Compensation Committee did not make any significant changes to our executive compensation program based on its review of the 2024 voting results.
To ensure investor views are incorporated into our planning process, we engage with stockholders on an ongoing basis to gather their perspectives. Through this stockholder outreach, we have established important feedback channels that serve as a valuable resource for ongoing input from our stockholders. Our Board of Directors values the opinions of our stockholders, and our Compensation Committee will continue to consider the results of future stockholder votes, as well as feedback received throughout the year, when making compensation decisions for our executives, including our NEOs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.